BioActor-receives-ISO9001:2015-certification

BioActor receives ISO 9001:2015 certification

BioActor receives ISO 9001:2015 certification

Maastricht, Netherlands, May 19th, 2022

Press release
BioActor proudly announces to have been awarded the ISO 9001:2015 certification! ISO is one of the most rigorous and acclaimed internationally recognised standards, which ensures that BioActor’s products and services meet the needs of customers through an effective quality management system.

BioActor-receives-ISO9001:2015-certification

ISO 9001:2015

BioActor is dedicated to continuous improvements in its products and services and strives to surpass customer expectations, evidenced by the ISO 9001:2015 accreditation. In order to become ISO 9001:2015 compliant, the BioActor team, based in Maastricht – the Netherlands, underwent a comprehensive company-wide audit including a management system documentation review, pre-audit, initial assessment, and ultimately, clearance of the minor non-conformities.

The BioActor team were audited by Bureau Veritas and obtained their certificate in May 2022.

BioActor’s Quality Manager, Myrto Papageorgiou says:

“I’m proud of our team for how we worked together and proved that our main aspiration is to satisfy our customers by providing them with high-quality products and services. It gives me great pride to receive the ISO 9001:2015 certificate and it highlights our commitment to continually improve for our customers “

Find our certificate here.

About BioActor

BioActor, based at the Maastricht Health Campus, Netherlands, is a life science company that has developed a range of proprietary bioactive ingredients for the nutrition & consumer health industries. The company focuses on the development of plant-based health ingredients for active living and healthy ageing. The goal is to provide the nutrition & consumer health industries with clinically tested innovations that confer a real health benefit to the consumer.

Feel free to contact BioActor via info@bioactor.com for more information on our products.

Further information can be found on: www.bioactor.com


BioActor-starts-new-clinical-trial-on-Actiful

Started new clinical trial with Actiful®

Started new clinical trial with Actiful®

Maastricht, Netherlands, May 4th, 2022

Press release
BioActor has officially started a new clinical trial with Actiful® in healthy middle-aged adults. Actiful® is BioActor’s innovative citrus and pomegranate complex ingredient designed to enhance vitality and support an active lifestyle.

BioActor-starts-new-clinical-trial-on-Actiful

The new randomized double-blind placebo-controlled study

BioActor announced today that it has officially started the new intervention study on Actiful®.

Actiful® is an orange and pomegranate complex with demonstrated health benefits such as improving blood flow,  increasing energy levels, improving mitochondrial efficiency and boosting mental well-being.

This is the second clinical study that will be conducted with Actiful® and it will be performed in collaboration with Maastricht University at the research facilities in Maastricht and Venlo.

Duting this new double-blind placebo-controlled study, 52 healthy middle-aged (40-65 years) will take the supplements (or the placebo) for a duration of 12 weeks. The aim of this study is to assess the effects of Actiful® on physical fitness, vitality and quality of life.

The primary outcome (VO2max) will be estimated by use of the Ekblom-Bak submaximal test, a novel test performed on a cycle ergometer.

Additionally, a sub-group of participants will undergo a skeletal muscle biopsy to explore the effect of Actiful® on mitochondrial biogenesis and muscle repair.

As we age, we tend to have less energy and lose vitality. Functional foods and dietary supplements containing polyphenols are seen as an excellent strategy for long term sustained energy production. BioActor is addressing this need by developing a unique product- Actiful®. This product consists of all-natural ingredients from oranges and pomegranates.

“I’m really excited to be part of this project as the combined effect of hesperidin and punicalagin on enhanced performance has never been studied before”, says Maria Imperatrice, the study executive researcher in Maastricht. “We are very curious to explore their effect on human exercise and deepen the knowledge of the effect of polyphenols on mitochondrial biogenesis and muscle regeneration.”

About BioActor

BioActor, based at the Maastricht Health Campus, Netherlands, is a life science company that has developed a range of proprietary bioactive ingredients for the nutrition & consumer health industries. The company focuses on the development of plant-based health ingredients for active living and healthy ageing. The goal is to provide the nutrition & consumer health industries with clinically tested innovations that confer a real health benefit to the consumer.

Feel free to contact BioActor via info@bioactor.com for more information on the possibilities Actiful® has to offer.

Further information can be found on:  www.actiful.eu and www.bioactor.com


BioActor-is-participating-in-Vitafoods-2022-meet-us-Booth-F140

Visit us at Vitafoods Europe 2022

Visit us at Vitafoods Europe 2022

April 22nd, 2022

We are happy to announce that BioActor will participate in Vitafoods 2022, the trade show that offers the opportunity to find out the latest trends in the field of dietary supplements, raw materials, and food and to network with other professionals from around the world. Visit us at Booth F140.

BioActor-is-participating-in-Vitafoods-2022-meet-us-Booth-F140

Meet us at Booth F140

Our team can’t wait to meet you online from May 2nd to May 13th, and in Geneva from May 10th to 12th.

You are welcome to come over for a coffee at our booth F140 to discuss new business opportunities and get an idea of how our science-based ingredient can help you achieve your product development goals.

Amongst the most exciting news, our team will be happy to present the recently concluded randomized clinical trials on our gut health and brain fitness solutions, MicrobiomeX® and Brainberry®.

Don’t miss it, we are looking forward to seeing you there!

Book a meeting!



    New-in-vitro-co-culture-model-study-published-with-citrus-flavonoid-extract

    New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®

    New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®

    Maastricht, Netherlands, April 21st, 2022

    Press release
    British Journal of Nutrition has recently published a new in vitro co-culture model study with a citrus flavonoid extract MicrobiomeX® and its metabolites, hesperetin and naringenin. The novel publication suggests that these citrus flavonoids, as well as their metabolites, may reduce intestinal inflammation.

    New-in-vitro-co-culture-model-study-published-with-citrus-flavonoid-extract

    New in vitro co-culture model study published with citrus flavonoid extract MicrobiomeX®

    MicrobiomeX® is a first-in-class Flavobiotic® developed by BioActor, that combines active ingredients from Citrus sinensis and Citrus paradisi. MicrobiomeX® has already been studied and reported to have various beneficial effects on the gut and immunity. MicrobiomeX® consists of standardised citrus flavonoids, that form active metabolites, hesperetin and naringenin, in the gut after being deglycosylated by the gut microbiota.

    In the recently published in-vitro study, a validated co-culture system of Caco-2/THP-1 cells as model for intestinal inflammation and cytokine-induced barrier disruption was used to determine the effects of citrus flavonoids and their metabolites on intestinal inflammation.

    During the research, cells were treated with citrus flavonoids, their metabolites, or a vehicle control. Additionally, cells were incubated with lipopolysaccharide (LPS), which is known to induce inflammation and deterioration in epithelial integrity.

    The conclusion highlights that hesperetin and naringenin significantly reduced NF-kB activity, leading to a reduction in intestinal inflammation. Pro-inflammatory cytokines IL-8, TNF-α and IL-6 were also significantly reduced after hesperetin and naringenin administration.

    The mechanism behind this reduction in inflammation can be ascribed to partial inhibition of the NF-κB signalling pathway.

    “We are very happy with the results of this study, as we were able to show that both the citrus flavonoids themselves and their metabolites are able to reduce inflammation in the intestine”, says Yala Stevens, CSO of BioActor. “These new scientific insights on MicrobiomeX® will allow us to consolidate its applications to products targeting gut health and immune function”.

    About BioActor

    BioActor, based at the Maastricht Health Campus, Netherlands, is a life science company that has developed a range of proprietary bioactive ingredients for the nutrition & consumer health industries. The company focuses on the development of plant-based health ingredients for active living and healthy ageing. The goal is to provide the nutrition & consumer health industries with clinically tested innovations that confer a real health benefit to the consumer.

    Feel free to contact BioActor via info@bioactor.com for more information on the possibilities MicrobiomeX® has to offer.

    Further information can be found on:  www.microbiomex.com and www.bioactor.com


    Press release new publication on Bonolive BioActor

    New clinical study on patented olive leaf extract Bonolive® shows joint health benefits

    New clinical study on patented olive leaf extract Bonolive® shows joint health benefits

    Maastricht, Netherlands, February 8th, 2022

    Press release
    Therapeutic Advances in Musculoskeletal Disease has recently published a new clinical study with Bonolive®, a patented bone and joint health ingredient based on olive polyphenol. The new publication suggests that Bonolive® may improve joint functional capacity and reduce knee pain.

    Press release new publication on Bonolive BioActor

    New randomized clinical trial published with Bonolive®

    Bonolive® is a natural polyphenol extract from olive leaves, developed by BioActor. Bonolive® was already studied for bone protecting effects in post-menopausal women and is covered by a patent on the bone health application of the extract.

    A recent randomized, double-blind, placebo-controlled trial including 124 subjects demonstrated a large and significant treatment effect of Bonolive® in improving joint discomfort and reducing pain in subjects with knee pain.

    Participants in the study received either a placebo or supplementation with a 125mg capsule containing Bonolive® (40% oleuropein), twice a day for 6 months.

    The conclusion indicates that Bonolive® was able to improve the KOOS score (Knee Injury and Osteoarthritis Outcome) and to reduce walking pain in subjects with knee pain.

    The researchers from the Liege University Hospital suggested that oleuropein may relieve nociceptive pain triggered by the mechanical strain because of its calcium channel blocker property.

    N-type calcium channels are indeed important for neuronal excitability and play a role in pain genesis. As a blocker of these channels, Bonolive® seems to produce an antinociceptive effect, thus reducing pain.

    These benefits were not associated with any adverse effect after 6 months of treatment, showing excellent tolerability of the extract. Moreover, the study confirmed yet again the great bioavailability of Bonolive®. The main metabolites of the extract, oleuropein aglycone, hydroxytyrosol and homovanillyl alcool were measured and showed a rapid rise in the urine of all treated subjects.

    This study was conducted in the context of a collaboration with Nestlé Health Science, aiming to strengthen the scientific evidence for the benefits of Bonolive®.

    “We are proud of the results achieved thanks to this collaboration”, says Hans van der Saag, CEO and founder of BioActor. “Mobility is extremely important for the quality of life and a core indicator of healthy ageing. These new scientific insights on Bonolive® will allow us to expand its applications to mobility targeting products”.

    About BioActor

    BioActor, based at the Maastricht Health Campus, Netherlands, is a life science company that has developed a range of proprietary bioactive ingredients for the nutrition & consumer health industries. The company focuses on the development of plant-based health ingredients for active living and healthy ageing. The goal is to provide the nutrition & consumer health industries with clinically tested innovations that confer a real health benefit to the consumer.

    Feel free to contact BioActor via info@bioactor.com for more information on the possibilities Bonolive® has to offer.

    Further information can be found on:  www.bonolive.com and www.bioactor.com


    New Publication in Nutrients shows beneficial effects of MicrobiomeX® in TIM-2 model

    New Publication in Nutrients shows beneficial effects of MicrobiomeX® in TIM-2 model

    Maastricht, The Netherlands, 17th November 2021

    Press release
    The effect of MicrobiomeX®, a natural citrus ingredient consisting of specific active flavonoids, was evaluated through in-vitro examination in the TIM-2 model. The study results, recently published in a peer-reviewed journal, showed that MicrobiomeX® can beneficially change the microbiota composition and Short-Chain Fatty Acids production of human volunteers.

    In-Vitro Study on MicrobiomeX®

    A recent in-vitro study in the TIM-2 dynamic model of the large intestine has shown that MicrobiomeX® has a profound effect on the microbiota composition, already after three days.

    MicrobiomeX® is a natural Flavobiotics® from citrus fruits, designed to support gut & immune health by lowering gut inflammation and beneficially shifting the gut microbiome composition.

    This innovative flavonoid-based ingredient has already shown in a first clinical trial to boost overall gut health by positively changing the short-chain fatty acid composition. In addition, lower faecal calprotectin levels (an important biomarker of gut inflammation) were found in the treatment group.

    The outcome of the new in-vitro study, recently published in Nutrients, showed that the consumption of MicrobiomeX® led to a microbiota composition typical of a person following a healthy plant-based diet rich in fibre.

    The study was conducted by the group of Professor Koen Venema, who is also the last author of the publication.

    The purpose of the study was to find out whether low doses of MicrobiomeX® – 250mg and 350mg – would have a short term effect on the human gut microbiota and the production of short-chain fatty acids.

    The study was carried out in the TIM-2 model with faecal samples from 7 human volunteers. These samples were either treated with two different doses of MicrobiomeX® or a control. Already after 48 hours, the first differences between the treatment and the control could be observed, which became significant after 72 hours.

    Interestingly, a potent butyrate-producing class of bacteria – Roseburia spp – was significantly increased with both the 250mg and the 350mg doses, whereby the increases were clearly dose-dependent.

    Click here to download the complete publication.

    About BioActor

    BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

    Feel free to contact us for more information on the possibilities MicrobiomeX® has to offer.

    Further information can also be found on: www.microbiomex.com


    Brain imaging research

    BioActor and UM establish a Public Private Partnership to study the benefits of Aronia on cognition

    BioActor and UM establish a Public Private Partnership to study the benefits of Aronia on cognition

    Maastricht, The Netherlands, September 22nd, 2021

    Press release
    BioActor already collaborates with Maastricht University in several areas, but this Private public partnership marks the start of an ambitious and comprehensive joint research programme, which will last three years, and aims to unravel possible mechanisms that make Aronia Melanocarpa such a powerful bioactive to improve brain fitness

    Brain imaging research

    The joint research programme will study the benefits of Aronia on cognition

    BioActor and Maastricht University (“UM”) established a Public Private Partnership (“PPP”) to study the effects of Aronia Melanocarpa on brain fitness and cognition. This PPP received a competitive grant from Health Holland and will last for 3 years.

    BioActor already collaborates with UM in several areas, but this PPP marks the start of an ambitious and comprehensive joint research programme to unravel possible mechanisms that make Aronia Melanocarpa such a powerful bioactive to improve brain fitness.

    The PPP will be led by Dr. Peter Joris and Professor Jogchum Plat of UM’s Department of Nutrition and Movement Sciences. BioActor will make available a senior scientist, Sanne Ahles, who has already coordinated a previous clinical study with BioActor’s proprietary aronia extract Brainberry®.

    The research programme will comprise a comprehensive clinical study, where besides cognitive parameters and blood biomarkers, brain scans will be made by Scannexus, specialist in Ultra High-Field MRI.

    Dr. Peter Joris, Assistant Professor at UM comments:
    “I’m very pleased with the establishment of this partnership with BioActor as it will allow us to explore mechanisms underlying beneficial effects of Aronia Melanocarpa on cognitive function, which may contribute to the prevention of cognitive impairment and ultimately dementia. Focus will be on brain insulin-sensitivity and vascular function assessed with brain MRI imaging in people at increased risk of cognitive impairment.”

    Dr. Yala Stevens, Chief Scientific Officer of BioActor comments:
    “This partnership with UM underscores our commitment to science and our passion for exploring research areas that have hitherto not been touched by others. That’s why we have decided to take a deep dive together with Dr. Peter Joris into the effects and mechanisms of aronia melanocarpa in the cognition and brain fitness space. I’m really curious what will come out of this research programme and excited to be able to share the results with the global nutrition science community.”

    About BioActor:

    BioActor is a life science company based on the Maastricht Health Campus and dedicated to research, develop and sell health ingredients addressing healthy ageing and active living. BioActor has a targeted portfolio of patented and branded health ingredients that are all based on food crops, clinically researched and produced in Europe.
    For more info: www.bioactor.com

    About Maastricht University:

    The current project is performed at the Department of Nutrition and Movement Sciences within the School of Nutrition and Translational research in Medicine (NUTRIM), and will be integrated within an excellent scientific environment that offers facilities to perform state-of-the-art multi-disciplinary research, such as a unique Metabolic Research Unit (MRUM) and advanced MRI systems at Scannexus – an internationally focused brain MRI imaging center – facilities in Maastricht.


    Arabinoxilan vaccine efficiency.j

    Naxus® positive clinical results on its contribution towards an effective vaccination in elderly individuals

    Naxus® positive clinical results on its contribution towards an effective vaccination in elderly individuals

    Maastricht, The Netherlands, September 8th, 2021

    Press release
    The results of the recent clinical trial displayed the significant benefits of Naxus® towards the efficacy of vaccines . Naxus® led to a significant positive changes in parameters such as, cytokine production, microbiota composition, and fecal PH compared to other non-digestible polysaccharides.

    Arabinoxilan vaccine efficiency.j

    The Clinical Benefits of Naxus®

    Immunosenescence is the process of deterioration of immune system functionality, mostly present in the elderly. Effective vaccination of the older adult is therefore a rising concern and a point to consider. BioActor has published the results of its recent clinical trial on Naxus®, an arabinoxylan extract from wheat endosperm on vaccination efficiency in Nutrients (Laue et al. 2021). Naxus® was compared to other non-digestible polysaccharides (NSPs): Wellmune®, Oatwell®, a beta-glucan from shiitake and exopolysaccharide preparation from L. Mucosae. NSPs are known for their promising effects on improving the immune response. From all investigated products, daily supplementation of Naxus® improved vaccination efficiency most effectively. Naxus® was further found to be safe, tolerable and feasible as a supplement.

    The participants that completed the randomized, placebo-controlled, double-blind study were 231 of 239 subjects. Participants where split into six groups, each consuming a different non-digestible polysaccharide or control: Naxus®, Oatwell®, Wellmune®, a beta-glucan preparation from shiitake prepared according to a pre-specified procedure or an exopolysaccharide preparation from L. Mucosae for the duration of 5 weeks. The study showed significant beneficial changes in the Naxus® group compared to control in several parameters such as, cytokine production, microbiota composition and fecal pH.

    Some of these beneficial changes could be linked with the significant increase in the abundance of Bifidobacterium in the gut that Naxus® demonstrated in the study. This increase is associated with a reduced infection, duration of influenza and severity of the common cold. Furthermore, an increase in IFN-γ was observed as a result of Naxus® consumption. IFN-y cytokines are produced by natural killer cells, which function as the first in line of defense against viral infections.

    The researchers conclude that Naxus® is the most effective compound tested, compared to other NSPs, in this study to promote an adjuvant effect on the immune response to vaccination.
    Although lack of understanding of the underlying mechanism, strong immunomodulatory are likely to explain the effect. Previous In-vitro work already demonstrated convincing links between the innate immune system and Naxus®. An enhanced vigilance of the immune system could therefore be the key to an explanation of the vaccination efficiency.

    In conclusion, the findings in this study show a valuable contribution of Naxus® to our body, functioning as a prebiotic and enhancing protection against unwanted intruders!

    BioActor’s Chief Scientific Officer, Yala Stevens says: “I am very happy with the publication of the vaccination trial, as it is the culmination of a great effort and collaboration involving multiple partners. These interesting results I believe are also very relevant and deserve to be shared within the scientific community and beyond.”

    Naxus® can be applied in various finished dosage forms, including bars, granola, flapjacks, capsules, stick packs, scoopable powder.

    About BioActor

    BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

    Feel free to contact us via info@bioactor.com for more information on the possibilities Naxus® has to offer.
    Further information can be found on: www.naxus.nl


    Berries anthocyanins

    The effects of berry anthocyanins on cognition - New publication

    The effects of berry anthocyanins on cognitive performance – New publication from BioActor in collaboration with Maastricht University

    Maastricht, The Netherlands, July 8th, 2021

    Press release
    The systematic review recently published in the International Journal of Molecular Sciences was conducted by BioActor in collaboration with Maastricht University and reviewed the effects of berry anthocyanins on cognitive performance.

    Berries anthocyanins

    Systematic review on berry anthocyanins and cognition

    The International Journal of Molecular Sciences has recently published a systematic review about the Berry Anthocyanins’ effect on Cognitive Performance. The research was conducted by S. Ahles, clinical researcher at BioActor, in collaboration with the Maastricht University’s Department of Nutrition and Movement Sciences, School of Nutrition and Translational Research in Metabolism (NUTRIM).

    This systematic review of randomized Placebo-Controlled Studies in Humans provides further evidence into the beneficial effects of berry anthocyanins on cognitive performance such as attention and psychomotor speed, executive function, and memory. Moreover, effects on vascular function and cardiometabolic risk markers were investigated.

    Anthocyanins are a specific type of flavonoids abundantly found in various berries such as blueberry, black raspberry, and Aronia berry, to which these molecules confer the specific colours. These compounds offer a promising approach to improve cognitive performance and/or lower the risk of cognitive decline.

    Ahles commented: “We are proud to report the achieved results providing evidence for the beneficial effects of berry anthocyanin on cognitive function. The observed health effects might be due to the anthocyanin-induced improvements in vascular function and blood pressure. Moreover, we found that the composition of the intervention product may play an important role as the bioactivity of anthocyanins is known to be dependent on their chemical structure. Future studies should focus on exploring a potential causal link between the beneficial effects on cognitive performance and improvement in vascular function and cardiometabolic risk markers.”

    BioActor’s interest in berry anthocyanins has resulted in the development of the first-ever Aronia Berry extract targeting cognitive performance. The ingredient, branded under the name “Brainberry®”, was already tested in a randomized placebo-controlled clinical trial in healthy individuals and an observational study conducted with e-sports gamers, while a second RCT study, assessing its acute effect on cognition, is ongoing.

    About BioActor

    BioActor, based in Maastricht, Netherlands, is a product development company that has developed a range of proprietary bioactive ingredients for the nutrition & healthcare industry. The company focuses on the development of innovative activities that address active living and healthy aging. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer a real health benefit to the consumer.

    Feel free to contact us via info@bioactor.com for more information on the possibilities Brainberry® has to offer.
    Further information can be found on: www.brainberry.eu


    Gut microbiome

    Partnership between BioActor and Wageningen University to integrate microbiota and immunity into a miniaturized assay

    Partnership between BioActor and Wageningen University to integrate microbiota and immunity into a miniaturized assay

    Maastricht, The Netherlands, June 28th, 2021

    Press release
    The intestine-on-a-chip model is a promising technology to revolutionize the currently used in vitro methods to better emulate the complex in vivo human intestinal physiology

    Gut microbiome

    The project

    BioActor is thrilled to be an industrial partner of the INIMINI project, in partnership with Wageningen University & Research. The project “INIMINI-health: immune- and microbiota-competent intestine-on-a-chip to study health-promoting nutrition and drugs”, funded by Health Holland, aims to integrate microbiota and immunity into a miniaturized assay.

    The intestine-on-a-chip model is a promising technology to revolutionize the currently used in vitro methods to better emulate the complex in vivo human intestinal physiology, providing an alternative for animal models in which species differences and ethical concerns are problematic. With this innovative tool, it will be possible to explore food interventions (and food-drug interactions) that can be used to prevent a compromised intestinal immune system and/or to treat the consequences.

    The project consortium is a unique combination of knowledge partners (TO2 and academic institutes), six industry partners (Dutch and international) along the value chain, and the Dutch Maag Lever Darm Stichting (MLDS) as the key patient organization. BioActor will provide its knowledge on the physiological effects of flavonoids and arabinoxylans on the gut microbiota and the immune system.

    This embodies the ‘quadruple helix’ approach that contributes to the overarching mission of “vital functioning citizens in a healthy economy”.

    About BioActor
    BioActor, based in Maastricht, Netherlands, is a life science company that develops and markets proprietary bioactives for the nutrition & healthcare industries. The company focuses on clinically validated innovative bioactives that address active living and healthy ageing. The goal is to provide the nutrition & healthcare industry with science-based innovations that confer real health benefits to the consumer.

    For further information, see www.bioactor.com